NCT07180056View on ClinicalTrials.gov

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

229

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

February 28, 2033

Conditions
Breast Cancer
Interventions
DRUG

CDK4/6 inhibitor

abemaciclib OR ribociclib

Trial Locations (1)

200127

Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai

All Listed Sponsors
lead

Wenjin Yin

OTHER